Shinpoong Makes Exclusive Licensing Agreement for Tesmilifene

Published: 2005-02-01 06:56:00

Updated: 2005-02-01 06:56:00

Shinpoong Pharmaceutical Co. Ltd. announced last week that it made an exclusive domestic licensing agreement with YM BioSciences Inc.'s tesmilifene, a novel anticancer agent currently undergoing a multinational phase III clinical trial in patients with advanced breast cancer.

Discovered an...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK